Quest Diagnostics Inc. (DGX) is a publicly traded Healthcare sector company. As of October 8, 2026, DGX trades at $226.97 with a market cap of $25.21B and a P/E ratio of 24.37. DGX moved +0.48% today. Year to date, DGX is +30.65%; over the trailing twelve months it is +24.83%. Its 52-week range spans $157.20 to $248.84. Analyst consensus is buy with an average price target of $255.00. Rallies surfaces DGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for DGX shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $226.97 |
| Market Cap | $25.21B |
| P/E Ratio | 24.37 |
| EPS | $9.54 |
| Dividend Yield | 0.86% |
| 52-Week High | $248.84 |
| 52-Week Low | $157.20 |
| Volume | 18.32K |
| Avg Volume | 0 |
| Revenue (TTM) | $11.56B |
| Net Income | $1.11B |
| Gross Margin | 33.11% |
11 analysts cover DGX: 0 strong buy, 7 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $255.00.